Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
- Publication date
- 1 January 2019
- Publisher
- Providence St. Joseph Health Digital Commons